Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.

doi:10.1016/j.ejca.2022.06.034

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.

European journal of cancer (Oxford, England : 1990) - 1 Oct 2022

Foy Jean-Philippe, Karabajakian Andy, Ortiz-Cuaran Sandra, Boussageon Maxime, Michon Lucas, Bouaoud Jebrane, Fekiri Dorssafe, Robert Marie, Baffert Kim-Arthur, Hervé Geneviève, Quilhot Pauline, Attignon Valéry, Girod Angélique, Chaine André, Benassarou Mourad, Zrounba Philippe, Caux Christophe, Ghiringhelli François, Lantuejoul Sylvie, Crozes Carole, Brochériou Isabelle, Pérol Maurice, Fayette Jérôme, Bertolus Chloé, Saintigny Pierre

Abstract excerpt

INTRODUCTION: Identification of tumours harbouring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. Our objective was to develop a reliable and stable scoring system to identify those immunologically active tumours. METHODS: Using gene expression profiles of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Cetuximab

Share to Head and Neck Neoplasms

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Programmed Cell Death 1 Receptor

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed

Identifiers

PMID: 36038492
DOI: 10.1016/j.ejca.2022.06.034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.PMID 36038492Read ↗

Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinomaSemantic proximity Read ↗

Connecting Baseline Immune Exhaustion in Hot Tumors to Oral Cancer Recurrence and Nodal MetastasisSemantic proximity Read ↗

Integrative immune subtyping of HNSCC reveals clinically relevant phenotypes and treatment-associated transitionsSemantic proximity Read ↗

Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responsesSemantic proximity Read ↗

High-Sensitivity PD-L1 Staining Using Clone 73-10 Antibody and Spatial Transcriptomics for Precise Expression Analysis in Non-Tumorous, Intraepithelial neoplasia, and Squamous Cell Carcinoma of Head and NeckSemantic proximity Read ↗

External validation of the VIGex gene-expression signature as a novel predictive biomarker for immune checkpoint treatmentSemantic proximity Read ↗

Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.Semantic proximity Read ↗

High-Dimensional Spectral Cytometry Reveals Therapeutically Relevant Immune Subtypes in Gastric CancerSemantic proximity Read ↗

A Clinically Translatable Immune-based Classification of HPV-associated Head and Neck Cancer with Implications for Biomarker-Driven Treatment Deintensification and ImmunotherapySemantic proximity Read ↗

Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.Semantic proximity Read ↗

Predictive and prognostic factors for immunotherapy response in head and neck squamous cell carcinoma: a narrative review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.